4.7 Article

Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism

Journal

BRAIN
Volume 140, Issue -, Pages 98-117

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/brain/aww261

Keywords

Parkinson's disease; PINK1; heterozygous mutation; ubiquitin; mitophagy

Funding

  1. Swedish Parkinson Academy
  2. Swedish Parkinson Foundation (Parkinsonfonden)
  3. Swedish National Health Services (ALF)
  4. Bundy Academy, Lund, Sweden
  5. National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) [NS085070]
  6. Michael J. Fox Foundation for Parkinson's Research
  7. Foundation for Mitochondrial Medicine
  8. Mayo Clinic Center for Regenerative Medicine (CRM)
  9. Center for Individualized Medicine (CIM)
  10. Center for Biomedical Discovery (CBD)
  11. Marriott Family Foundation
  12. Gerstner Family Career Development Award
  13. American Parkinson Disease Association (APDA)
  14. Uehara Memorial Foundation
  15. NIH/NINDS [NS078086, NS38377, MDSCRF 2007-MSCRFI-0420-00, 2009-MSCRFII-0125-00, MDSCRF 2012-MSCRFII-0268-00, MDSCRF 2013-MSCRFII-0105-00]
  16. Mayo Clinic Center for Individualized Medicine (CIM)
  17. Mayo Clinic Florida Neuroscience Focused Research Team Awards
  18. European Research Council
  19. Swedish Research Council
  20. Swedish Brain Power
  21. ALF
  22. NHMRC [APP1084560]
  23. CONCYT PhD program
  24. MultiPark, Lund University, Sweden
  25. JPB Foundation
  26. Foundation's Parkinson's Disease Program [M-1]

Ask authors/readers for more resources

It has been postulated that heterozygous mutations in recessive Parkinson's genes may increase the risk of developing the disease. In particular, the PTEN-induced putative kinase 1 (PINK1) p.G411S (c.1231G>A, rs45478900) mutation has been reported in families with dominant inheritance patterns of Parkinson's disease, suggesting that it might confer a sizeable disease risk when present on only one allele. We examined families with PINK1 p.G411S and conducted a genetic association study with 2560 patients with Parkinson's disease and 2145 control subjects. Heterozygous PINK1 p.G411S mutations markedly increased Parkinson's disease risk (odds ratio = 2.92, P = 0.032); significance remained when supplementing with results from previous studies on 4437 additional subjects (odds ratio = 2.89, P = 0.027). We analysed primary human skin fibroblasts and induced neurons from heterozygous PINK1 p.G411S carriers compared to PINK1 p.Q456X heterozygotes and PINK1 wild-type controls under endogenous conditions. While cells from PINK1 p.Q456X heterozygotes showed reduced levels of PINK1 protein and decreased initial kinase activity upon mitochondrial damage, stress-response was largely unaffected over time, as expected for a recessive loss-of-function mutation. By contrast, PINK1 p.G411S heterozygotes showed no decrease of PINK1 protein levels but a sustained, significant reduction in kinase activity. Molecular modelling and dynamics simulations as well as multiple functional assays revealed that the p.G411S mutation interferes with ubiquitin phosphorylation by wild-type PINK1 in a heterodimeric complex. This impairs the protective functions of the PINK1/parkin-mediated mitochondrial quality control. Based on genetic and clinical evaluation as well as functional and structural characterization, we established p.G411S as a rare genetic risk factor with a relatively large effect size conferred by a partial dominant-negative function phenotype.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available